Ethinylestradiol/levonorgestrel continuous - Pfizer

Drug Profile

Ethinylestradiol/levonorgestrel continuous - Pfizer

Alternative Names: EE/Levo continuous - Pfizer; EE/LNG continuous - Pfizer; Levo/EE continuous - Pfizer; Levonorgestrel/ethinlyestradiol continuous - Pfizer; Librel®; LNG/EE continuous - Pfizer; Lybrel

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy
  • Discontinued Premenstrual dysphoric disorder; Premenstrual syndrome

Most Recent Events

  • 07 Jun 2011 Generic equivalent approved in USA for Contraception/Pregnancy (Prevention)
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 02 Jul 2007 Launched for Contraception/Pregnancy (Prevention) in USA (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top